Testosterone and prostate safety

Frontiers of Hormone Research

Volumn 37, Issue , 2009, Pages 197-203

  Morgentaler, A ^a   Schulman, C ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CANCER INCIDENCE; CANCER RISK; CLINICAL TRIAL; DIGITAL RECTAL EXAMINATION; DISEASE EXACERBATION; DRUG SAFETY; HORMONAL THERAPY; HORMONE DEFICIENCY; HUMAN; HYPOGONADISM; LONGITUDINAL STUDY; MONITORING; POPULATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; REVIEW; RISK; SYMPTOM; TESTOSTERONE BLOOD LEVEL; TUMOR BIOPSY; CHEMICALLY INDUCED DISORDER; MALE; PROSTATE TUMOR;

CLINICAL TRIALS AS TOPIC; HUMANS; LONGITUDINAL STUDIES; MALE; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 59849091022     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000176054     Document Type: Review

References (26)

1. Morgentaler A: Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 2006;50:935-939.
2. Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297.
3. Dean JD, Carnegie C, Rodzvilla J, Smith T: Long-term effects of Testim 1% testosterone gel in hypog-onadal men. Rev Urol 2004;6:S22-S29.
4. Rhoden EL, Morgentaler A: Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Int J Impot Res 2006;18:201-205.
5. Wang C, Cunningham G, Dobs A, et al: Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone density in hypogonadal men. J Clin Endocrinol Metab 2004;89:2085-2098.
6. Rhoden EL, Morgentaler A: Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 2003;170:2348-2351.
7. D'Amico AV, Roehrborn CG: Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol 2007;8: 21-25.
8. Rhoden EL, Morgentaler A: Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350:482-492.
9. Morgentaler A, Bruning CO 3rd, DeWolf WC: Incidence of occult prostate cancer among men with low total or free serum testosterone. JAMA 1996;276:1904-1906.
10. Morgentaler A, Rhoden EL: Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen of 4.0 ng/ml or less. Urology 2006;68: 1263-1267.
11. Hsing AW: Hormones and prostate cancer: what's next? Epidemiol Rev 2001;23:42-58.
12. Eaton NE, Reeves GK, Appleby PN, Key TJ: Endo -genous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 1999;80:930-934.
13. Stattin P, Lumme S, Tenkanen L, et al: High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 2004;108:418-424.
14. Barrett-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL: A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res 1990;50:169-173.
15. Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ: Serum testosterone and the risk of pros -tate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005;14: 2257-2260.
16. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ: Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-1126.
17. Marks LS, Mazer NA, Mostaghel E, et al: Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006;296:2351-2361.
18. Morgentaler A: Testosterone replacement therapy and prostate cancer. Urol Clin North Am 2007;34: 555-363.
19. Fowler JE, Whitmore WF Jr: The response of meta -static adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981;126:372-375.
20. Morgentaler A: Testosterone deficiency and pros -tate cancer: emerging recognition of an important and troubling relationship. Eur Urol 2007;52: 623-625.
21. Isom-Batz G, Bianco FJ Jr, Kattan M W, Mulhall JP, Lilja H, Eastham JA: Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 2005;173:1935-1937.
22. Hoffman MA, DeWolf WC, Morgentaler A: Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000;163:824-827.
23. Kaufman JM, Graydon RJ: Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004;172:920-922.
24. Agarwal PK, Oefelein MG: Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005;173:533-536.
25. Sarosdy MF: Testosterone replacement for hypogo-nadism after treatment of early prostate cancer with brachytherapy. Cancer 2007;109:536-541.
26. Behre HM, Bohmeyer J, Nieschlag E: Prostate volume in testosterone treated and untreated hypogo-nadal men in comparison to age-matched normal controls. Clin Endocrinol 1994;40:341-349.